Clearmind Medicine Inc. announced the publication of a U.S. patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of cocaine addiction. The application strengthens Clearmind's growing intellectual property portfolio and reinforces MEAI's potential to address a major unmet medical need. Cocaine use disorder affects millions worldwide and currently has no FDA-approved pharmacological treatment.
The global market for cocaine addiction treatment is estimated at $1.36 billion in 2025 and is projected to grow to $2.03 billion by 2032, highlighting the urgent demand for new and effective solutions. MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalable alternative to existing behavioral interventions.
